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Abstract
 
Natural tumor surveillance capabilities of the host were investigated in six different mouse tu-
mor models where endogenous interleukin (IL)-12 does or does not dictate the efficiency of
the innate immune response. Gene-targeted and lymphocyte subset–depleted mice were used
to establish the relative importance of natural killer (NK) and NK1.1
 
1
 
 T (NKT) cells in pro-
tection from tumor initiation and metastasis. In the models examined, CD3
 
2
 
 NK cells were re-
sponsible for tumor rejection and protection from metastasis in models where control of major
histocompatibility complex class I–deficient tumors was independent of IL-12. A protective
role for NKT cells was only observed when tumor rejection required endogenous IL-12 activ-
ity. In particular, T cell receptor J
 
a
 
281 gene-targeted mice confirmed a critical function for
NKT cells in protection from spontaneous tumors initiated by the chemical carcinogen, meth-
ylcholanthrene. This is the first description of an antitumor function for NKT cells in the ab-
sence of exogenously administered potent stimulators such as IL-12 or 
 
a
 
-galactosylceramide.
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Introduction
 
It is generally accepted that the host immune status, partic-
ularly natural immune responses, is essential in controlling
the dissemination and growth of metastatic tumors. NK
cells mediate spontaneous cytotoxicity against MHC class
I–deficient tumor cells and their metastases (1), and they
have long been known to participate in the innate im-
mune response against transformed cells in vivo (1, 2).
However, only a few studies have reported a prominent
role for NK cells on the growth of primary tumors in mice
without using biological response modifiers to magnify the
response (2, 3). Certainly cytokines, such as type I IFN
and IL-12, are considered important in initiating the acti-
vation of NK cells in response to pathogens (4). More re-
cently, NKT cells have been isolated and characterized (5–
8), and their role in IL-12–mediated antitumor activity has
been defined (9).
 
NK1.1
 
1
 
 T (NKT)
 
1
 
 cells are defined as specialized popu-
 
lations of 
 
a
 
/
 
b
 
 T cells that coexpress some receptors of the
 
NK cell lineage (5). NKT cells consist mainly of CD4
 
2
 
CD8
 
2
 
double negative and CD4
 
1
 
 cells (6, 7), most of which ex-
press a restricted TCR repertoire comprising an invariant
V
 
a
 
14J
 
a
 
281 TCR 
 
a
 
 chain (8) associated with polyclonal
V
 
b
 
8, V
 
b
 
7, and V
 
b
 
2 TCR 
 
b
 
 chains. A TCR J
 
a
 
281 gene-
targeted mouse produced by Cui et al. (9) confirmed the
requirement of invariant V
 
a
 
14J
 
a
 
281 TCR for the devel-
opment of most NKT cells (10). These unusual regulatory
cells that bridge the innate and acquired immune systems
recognize CD1d-bound glycolipid ligands such as 
 
a
 
-galac-
tosylceramides (
 
a
 
-GalCer [11, 12]) and glycosylphosphati-
dylinositols (13). NKT cells are present in most tissues
where T cells are found, in particular the liver, bone mar-
row, spleen, and thymus (14–16). Thymus and liver con-
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a
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a
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a
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tain primarily CD1d-dependent J
 
a
 
281-dependent NKT
cells, whereas spleen and bone marrow are enriched in
CD1d-independent J
 
a
 
281-independent NKT cells (17,
18). NKT cells have the peculiar potential to very rapidly
secrete large amounts of Th1 and Th2 cytokines (5, 19,
20), but also express perforin and surface molecules such as
Fas ligand (21, 22). After culture in the presence of IL-2,
NKT cells can mediate lysis through TCR, NK1.1, or
CD16, and kill classical NK-sensitive targets such as YAC-1
in vitro (23, 24). The NK1.1 molecule, which activates the
cytolytic function of NK cells (25, 26) and NKT cells (27),
could also activate IFN-
 
g
 
 secretion by both cell types, and
IL-12 mediated a similar effect (27).
Perhaps the strongest implication for a role for NKT
cells in Th1 immunity is in tumor rejection responses after
exogenous IL-12 (9, 28–30) or 
 
a
 
-GalCer (11, 31) adminis-
tration. The in vivo antitumor activity of 
 
a
 
-GalCer strongly
resembles the antitumor activity mediated by IL-12 (9, 32),
and indeed 
 
a
 
-GalCer mediates its effects by inducing IL-12
production by dendritic cells (DCs) and IL-12 receptor and
IFN-
 
g
 
 expression by NKT cells (33). Although it is likely
that endogenously produced IL-12 may also stimulate
NKT cells to produce IFN-
 
g
 
 and activate NKT cell cyto-
lytic function, no study to date has evaluated the natural
ability (i.e., not exogenously activated by IL-12 or 
 
a
 
-Gal-
Cer) of NKT cells to reject tumor growth or metastasis.
These studies teach us something about the therapeutic
benefit and mechanism of IL-12 or 
 
a
 
-GalCer, but very lit-
tle about the natural tumor surveillance capabilities of
NKT cells. Here, we have evaluated several tumor rejec-
tion models in naive mice in which endogenous IL-12 does
or does not regulate the efficiency of the innate immune
response. For the first time, we describe a critical role for
NKT cells and endogenous IL-12 in protection from spon-
taneous tumors initiated by the chemical carcinogen, meth-
ylcholanthrene (MCA).
 
Materials and Methods
 
Mice.
 
Inbred C57BL/6 (B6) mice were purchased from The
Walter and Eliza Hall Institute of Medical Research. B6 TCR
J
 
a
 
281–deficient (B6.J
 
a
 
281
 
2
 
/
 
2
 
) mice were obtained after eight
backcrosses of the (129 
 
3 
 
B6)F
 
1
 
 J
 
a
 
281
 
2
 
/
 
2
 
 mice (5) with B6
mice. B6 perforin-deficient (B6.P
 
2
 
/
 
2
 
) mice (34; from Dr. Guna
Karupiah, John Curtin School of Medical Research, Canberra,
Australia) and B6 IL-12p40–deficient (B6.IL-12p40
 
2
 
/
 
2
 
) mice
(35; Hoffman-La Roche) were bred at the Austin Research Insti-
tute Biological Research Laboratories. Mice of 4–8 wk of age
were used in all experiments in accordance with Animal Experi-
mental Ethics Committee guidelines.
 
Cell Culture.
 
The mouse tumor cell lines, YAC-1, RM-1,
and EL4-S3 (
 
b
 
2-microglobulin deficient; provided by Dr. James
McCluskey, University of Melbourne, Melbourne, Australia)
were grown in culture as described previously (36, 37). Sarcomas
derived from MCA-treated B6 or B6.J
 
a
 
281
 
2
 
/
 
2
 
 mice were main-
tained as described above. Flow cytometric sorting of NK, NKT,
and T cells was performed using a FACStar
 
PLUS™
 
 (Becton Dick-
inson [18]), and sort purities were always 97% or higher.
 
51
 
Cr-Release Assays.
 
The sensitivity of MCA-induced sarco-
mas to mouse NKT cells was determined as follows. Sorted NKT
cells (as above) from the thymi or livers of B6 and B6.P
 
2
 
/
 
2
 
 mice
were isolated and assessed as effectors in 4- and 18-h 
 
51
 
Cr-release
assays against labeled target cells as described (38). In some wells,
NKT cells were incubated with IL-2 (50 U/ml) and IL-12 (20
pg/ml) throughout the assay. Sorted liver NK cells and thymus T
cells were used as controls for NKT cells from each organ. Each
experiment was performed at least twice at four different E/T ra-
tios (20:1 shown) using duplicate samples.
 
Tumor Surveillance In Vivo.
 
NK and NKT cell function was
examined in various different tumor models as described (36, 37).
In model 1, groups of five mice were injected intraperitoneally
with increasing numbers of EL4-S3 or RM-1 tumor cells, and
were observed daily for tumor growth for 100 d by monitoring
the development of ascites in mice. Some groups of B6 mice
were depleted of NK cells or T cells in vivo by treatment with
100 
 
m
 
g anti-NK1.1 (PK136) or anti-Thy1 (T24/31.7) mAb, re-
spectively, on days 
 
2
 
2 and 0 (day of intraperitoneal tumor inoc-
ulation) and weekly thereafter. Depletion of NK and NKT cells
by anti-NK1.1 using this protocol was effective as determined by
flow cytometric analysis of spleen, thymus, and liver. Analysis of
NK1.1 versus TCR-
 
b
 
, IL-2R
 
b
 
 versus TCR-
 
b
 
, and mouse Ig
versus TCR-
 
b
 
 up to 7 d after anti-NK1.1 mAb administration
indicated that NK and NKT cells were depleted. In model 2,
groups of five mice were injected intravenously with up to 5 
 
3
 
10
 
4 
 
EL4-S3 tumor cells. 14 d later, their livers were removed and
fixed in Bouin’s solution, and surface lung metastases were
counted with the aid of a dissecting microscope. Some groups of
B6 mice were depleted of NK cells or T cells in vivo, as in model
1. In model 3, groups of five mice were injected subcutaneously
with RM-1 tumor cells (2 
 
3
 
 10
 
6
 
), and tumors were established
for 9 d. At this time, subcutaneous tumors were surgically re-
sected, and RM-1 cells were injected via the dorso-lateral tail
vein. Mice were killed 14 d later, the lungs were removed and
fixed in Bouin’s solution, and surface lung metastases were
counted with the aid of a dissecting microscope. Control experi-
ments were performed by inoculating mice with RM-1 cells in-
travenously and counting lung metastases 14 d later. Some groups
of B6 mice were depleted of NK cells or T cells in vivo, as in
model 1. The data for models 2 and 3 were recorded as the mean
(
 
n
 
 
 
5 
 
5) number of metastases 
 
6 
 
SEM. Significance was deter-
mined by an unpaired 
 
t
 
 test to determine a two-tail
 
 P 
 
value. In
model 4, groups of 16–35 mice were inoculated subcutaneously
in the right hind leg with 0.1 ml corn oil containing 1, 5, 25, or
100 
 
m
 
g MCA, and mice were monitored weekly for the devel-
opment of fibrosarcoma. Some groups of B6 mice were depleted
of NK cells or T cells in vivo by treatment with 100 
 
m
 
g anti-
NK1.1 or anti-Thy1 mAb, respectively, on days 
 
2
 
2 and 0 (day
of MCA inoculation) and weekly thereafter. Some MCA-
induced fibrosarcomas initiated in B6 and B6.J
 
a
 
281
 
2
 
/
 
2
 
 mice were
established in vitro, and were transplanted subcutaneously back
into B6 and B6.J
 
a
 
281
 
2
 
/
 
2
 
 mice.
 
Results and Discussion
 
NK and NKT Cell Numbers in Gene-targeted Mice.
 
Mul-
tiparameter flow cytometry was used to examine the status
of NK and NKT cells in the various mouse strains used in
this study. NKT cells were equivalently present in the
thymi of B6, B6.IL-12p40
 
2
 
/
 
2
 
, and B6.P
 
2
 
/
 
2
 
 strains, whereas
B6.J
 
a
 
281
 
2
 
/
 
2
 
 mice were markedly deficient in NKT cells 
663
 
Smyth et al.
 
in the thymus (references 9, 17, 18; data not shown). As re-
cently reported (17, 18), NKT cells were also reduced in
spleen and liver of B6.J
 
a2812/2 mice, but were not com-
pletely absent.
IL-12–independent MHC Class I–deficient Tumor Control
by NK Cells. Recently, we demonstrated that MHC class
I–negative RMA-S tumor growth was controlled in the
peritoneum by CD32NK1.11 NK cells in a perforin-
dependent manner (36). In a similar fashion, EL4-S3 and
RM-1 tumor cells inoculated intraperitoneally were cleared
less effectively in B6.P2/2 mice and B6 mice treated with
anti-NK1.1 mAb compared with wild-type B6 mice (Fig.
1, A and B). Rejection was IL-12 independent and did not
require T cells, in particular Va14Ja2811 NKT cells, as ev-
idenced by normal responses in B6.IL-12p402/2 and
B6.Ja2812/2 mice. Similar requirements have been dem-
onstrated using other MHC class I–deficient tumors, in-
cluding RMA-S (data not shown). All three cell lines were
class I deficient, and expressed low levels (RMA-S) or no
(EL4-S3, RM-1) CD1d (data not shown).
Innate Control of Experimental Metastases. Innate protec-
tion from metastases was then examined in two different
models in which NK1.11 cells control tumor colonization
(29, 37). In the first, we have demonstrated that NK1.11
cells protect B6 mice from experimental EL4-S3 liver me-
tastases in an IL-12–independent fashion (Fig. 2 A). Nei-
ther Thy11 nor specifically Va14Ja2811 NKT cells ap-
peared to control the number of hepatic colonies growing
in EL4-S3–inoculated mice. A significantly greater number
of lesions was observed in B6.P2/2 mice (P , 0.0001), in-
dicating that NK1.11 effectors primarily use perforin to re-
Figure 1. Elimination of intraperitoneally administered MHC class
I–negative syngeneic tumors in vivo is mediated by NK cells and is IL-12
independent. B6, B6.P2/2 (B6.P0), B6.IL-12p402/2 (B6.IL-12p400), or
B6.Ja2812/2 (B6.Ja2810) mice (five per group) were injected intraperito-
neally with tumor cells (10–105) in 0.2 ml PBS, as indicated. Some groups
of B6 mice were depleted of NK cells or T cells in vivo by treatment with
mAb, 100 mg anti-NK1.1, or anti-Thy1, respectively, on days 22 and 0
(day of intraperitoneal tumor inoculation), and weekly thereafter. Mice
were observed daily for tumor growth for 80 d by monitoring the devel-
opment of ascites in mice. Individual mice are represented by each sym-
bol. (A) EL4-S3 and (B) RM-1.
Figure 2. Innate control by NK and NKT cells in protection from tu-
mor metastasis. (A) Groups of five B6, B6.P2/2 (B6.P0), B6.IL-12p402/2
(B6.IL-12p400), or B6.Ja2812/2 (B6.Ja2810) mice were injected intrave-
nously with 500, 5,000, or up to 50,000 EL4-S3 tumor cells. 14 d later,
their livers were removed and fixed in Bouin’s solution, and surface lung
metastases were counted with the aid of a dissecting microscope. Some
groups of B6 mice were depleted of NK cells or T cells in vivo, as in the
legend to Fig. 1. (B) Groups of five B6, B6.P2/2 (B6.P0), B6.IL-12p402/2
(B6.IL-12p400), or B6.Ja2812/2 (B6.Ja2810) mice were injected subcuta-
neously with RM-1 tumor cells (2 3 106), and tumors were established
for 9 d. At this time, subcutaneous tumors were surgically resected, and
RM-1 cells were injected via the dorso-lateral tail vein. Mice were killed
14 d later, the lungs were removed and fixed in Bouin’s solution, and sur-
face lung metastases were counted with the aid of a dissecting microscope.
Control experiments were performed by inoculating mice with RM-1
cells intravenously and counting lung metastases 14 d later. Some groups
of B6 mice were depleted of NK cells or T cells in vivo, as in the legend
to Fig. 1. The data for A and B were recorded as the mean (n 5 5) num-
ber of metastases 6 SEM. Significant differences from B6 group were de-
termined by an unpaired t test to determine a two-tail P value (*P ,
0.0001; **P , 0.005).664 NKT Cell Antitumor Immunity
duce EL4-S3 tumor colonization. Clearly, the endogenous
response to EL4-S3 was NK cell mediated, and thus these
data contrast with previous studies that have suggested that
the anti-EL4 activity of exogenous IL-12 was mediated by
NKT cells (29).
In a second model, we have demonstrated previously
that NK1.11 cells using perforin protect B6 mice from
RM-1 metastasis (37). These studies also indicated that tu-
mor protection was compromised in B6 recombination ac-
tivating gene 1 (RAG-1)–deficient mice. Here, we have
extended these observations to demonstrate that NKT cells
are also partially responsible for RM-1 tumor protection.
Interestingly, the number of RM-1 colonies was very simi-
lar in B6.Ja2812/2 mice, B6.IL-12p402/2 mice, and B6
mice depleted of T cells with anti-Thy1 mAb (Fig. 2 B). It
remains to be determined what role NKT cells play in NK
cell–mediated protection from metastasis in this model, but
clearly endogenous IL-12 activity was required.
MCA-induced Fibrosarcoma Is Controlled by Va14 NKT
Cells in an IL-12–dependent Manner. Induction of fibrosar-
coma by MCA has been demonstrated previously to be
controlled by effector cells in a perforin-dependent and
IFN-dependent manner (38, 39). To date, however, no
extensive analysis has been undertaken to identify the sub-
Figure 3. NKT cells protect mice from MCA-induced sarcoma. Groups of B6, B6.P2/2 (B6.P0), B6.IL-12p402/2 (B6.IL-12p400), or B6.Ja2812/2
(B6.Ja2810) mice (number of mice in parentheses) were injected subcutaneously in the hind flank with (A) 100 mg or (B) 25 mg MCA diluted in 0.1 ml
corn oil. Mice were observed weekly for tumor development over the course of 50–180 d. Tumors .5 mm in diameter and demonstrating progressive
growth over 3 wk were counted as positive. Some groups of B6 mice were depleted of NK cells or T cells in vivo, as in the legend to Fig. 1. In C, sar-
coma development in B6, B6.P2/2 (B6.P0), and B6.Ja2812/2 (B6.Ja2810) mice was compared at several doses of MCA with data recorded at 180 d as a
percentage of the mice in each group (in parentheses). Significant differences from the B6 group were determined by a Fisher’s exact test (**P , 0.005;
***P , 0.02). Sarcomas derived from (D) B6.Ja2812/2 mice (Ja2810-MCA-1) and (E) B6 mice (B6-MCA-1) were transplanted at 106 or 107 cells sub-
cutaneously into groups of five B6.Ja2812/2 or B6 mice. Tumor growth was measured daily with a caliper square as the product of two diameters. Re-
sults were recorded as the mean tumor size (in cm2) 6 SEM, and are representative of two similar sarcomas transplanted into B6 and B6.Ja2812/2 mice.665 Smyth et al.
set of effector cells responsible for this immune surveillance.
Here, groups of B6 gene-targeted mice were injected subcu-
taneously with different doses of MCA, and fibrosarcoma
development was monitored for a period of 180 d (Fig. 3,
A–C). At the doses examined, B6.Ja2812/2 mice developed
tumors more frequently and earlier than B6 control mice. A
high (.70%) percentage of B6.Ja2812/2 mice treated with
100 and 25 mg of MCA developed tumors, whereas only
small proportions developed tumors in the corresponding
wild-type mice receiving MCA. At an MCA dosage of 1 mg,
30% of B6.Ja2812/2 mice developed fibrosarcoma, whereas
B6 mice remained tumor free (Fig. 3 C). Although IL-12
administration has been demonstrated to protect mice from
MCA-induced fibrosarcoma (40), our data in IL-12p402/2
mice are the first to describe a role for endogenous IL-12 in
this model (Fig. 3 A). Further evidence supporting a role for
Va14 NKT cells in the surveillance of MCA-induced tu-
mors was obtained in B6 mice that were chronically de-
pleted of NK1.11 or Thy11 cells (Fig. 3 A).
Depletion of CD81 cells did not increase the proportion
of mice developing fibrosarcoma (data not shown), in con-
cert with a similar study with CD8-deficient mice (38).
These data would argue against an important role for
CD81 T cells or CD81 lymphoid DCs that have been
demonstrated to contribute to some NK1.11 cell–mediated
tumor rejection responses driven by Flt3 ligand (41). Nev-
ertheless, Flt3 ligand treatment has been demonstrated pre-
viously to cause complete regression of tumors in mice
challenged with a syngeneic MCA-induced fibrosarcoma
(42), and thus endogenous responses to MCA-induced
spontaneous tumors may also involve intermediary DC
populations. In agreement with van den Broek et al. (38),
B6.P2/2 mice were more prone to MCA-induced sar-
coma, but always less so than B6.Ja2812/2 mice, suggest-
ing that more than one effector mechanism might be em-
ployed by NK1.11 cells in tumor surveillance. Given the
demonstrated surveillance defect in IFN-gR–deficient mice
(39), we are currently evaluating the level of protection in
IFN-g–deficient mice and mice deficient for both perforin
and IFN-g.
In concert with previous studies (38, 43), MCA-induced
sarcomas arising in B6 and B6.Ja2812/2 mice were gener-
ally both MHC class I negative and CD1d2 (data not
shown). Interestingly, when tumors were transplanted sub-
cutaneously from B6.Ja2812/2 mice, they grew far more
effectively in B6.Ja2812/2 mice than in control B6 mice.
Indeed, doses as high as 106 cells were effectively controlled
by B6 mice (Fig. 3 D) and (B6 3 129)F1 mice (as a control
for any potential minor 129 alloantigen expressed by the
tumor; data not shown). By contrast, sarcomas arising in B6
mice grew equally well in B6.Ja2812/2 and B6 mice after
transfer (Fig. 3 E). This observation is analogous to other
studies that have indicated that tumor initiation in immu-
nocompetent mice compared with immunocompromised
mice (e.g., B6.Ja2812/2 mice) may select for the growth of
less immunogenic tumors (43).
NKT Cells Can Directly Lyse Spontaneous Sarcomas Arising
in MCA-treated Mice. To test the possibility that MCA-
induced sarcomas were sensitive to direct lysis by NKT
cells, we determined the basal and activated cytotoxicity of
NKT cells against MCA-1 (a sarcoma derived from
B6.Ja2812/2 mice) and other tumor target cell lines (Fig.
4). Sorted NKT cells from the liver of B6 mice displayed
significant lysis of MCA-1 in a 4-h assay, particularly with
IL-2/IL-12 stimulation (Fig. 4 A). The lytic activity of
sorted resting liver NK cells was higher than resting NKT
cells against all the tumor target cells, with RM-1 tumor
cells comparatively insensitive to both NK and NKT cells.
Thymus NKT cells demonstrated lower levels of lysis of
MCA-1 than liver NKT cells, but they too demonstrated
enhanced lysis with IL-2/IL-12 stimulation. Although rest-
ing NKT cells did not display significantly greater lysis of
Figure 4. NKT cells directly lyse MCA-induced sarcoma. Thymus and
liver NKT cells (NK1.11TCR-b1) were sorted from B6 and B6.P2/2
mice, and were examined in (A) 4-h and (B) 18-h 51Cr-release assays for
direct lysis of a panel of labeled target cells as indicated. Some effector
cells were cultured in IL-2 (50 U/ml) and IL-12 (20 pg/ml) throughout
the course of the assay (1 IL-2/12). NKT effectors were tested at four
different E/T ratios (20, 5, 1, 0.5), with an E/T ratio of 20:1 shown. In
A, sorted liver NKT cells are compared with sorted liver NK cells. In B,
sorted thymus NKT cells are with sorted thymus T cells (CD41CD82
HSA2). The data is recorded as the mean 6 SEM, the spontaneous re-
lease of 51Cr was always ,15% (subtracted from all tests), and each test
was performed using duplicate samples. NT, not tested.666 NKT Cell Antitumor Immunity
target cells in 18-h assays, both thymus and liver NKT cells
stimulated in IL-2/IL-12 over the assay period were con-
siderably more lytic than in the 4-h assay (Fig. 4 B). By
contrast, NKT cells sorted from the thymi of B6.P2/2 mice
were unable to lyse MCA-1, even after IL-2/IL-12 stimu-
lation for 18 h, suggesting that NKT cell lysis of MCA-1
was strictly perforin dependent (Fig. 4 B). Control thymus
T cells did not display lytic activity in the absence or pres-
ence of IL-2/IL-12 against YAC-1 or MCA-1.
Concluding Remarks. The deficiency of a TCR Va14
Ja281–expressing NKT cell population in TCR Ja281
gene-targeted mice confirmed a critical function for NKT
cells in protection from spontaneous tumors initiated by
the chemical carcinogen, MCA. This is the first description
of an antitumor function for NKT cells in the absence of
exogenously administered IL-12 or a-GalCer. It remains
unclear whether NK cells are also contributing directly to
protection from MCA-induced sarcoma, as depletion of
NK1.11 cells serves to eliminate both NK and NKT cells.
The observations that the frequency of sarcomas is higher
in TCR Ja281 gene-targeted mice than in anti-NK1.1
mAb–treated mice, and that anti-NK1.1 mAb treatment
did not further increase the frequency of sarcomas in TCR
Ja281 gene-targeted mice (data not shown) suggested that
NK cells may not necessarily play any additional role.
However, the mAb depletion of NK1.11 cells over 6 mo is
not optimal, and a mouse deficient in NK cells but not
NKT or T cells would offer an ideal model mouse in
which to address this issue further.
The question of whether the antitumor activity of exog-
enous IL-12 is mediated by NKT cells rather than NK cells
also remains a topic of great debate. Data using bg/bg beige
(44) and Ja2812/2 (9) mice supports this hypothesis. How-
ever, by contrast, other experiments (even using the same
tumors) suggest that only NK cells mediate IL-12 antitu-
mor activities (45). We believe our data support the con-
cept that in some models both NK and NKT cells can have
important activities that protect against tumor metastasis or
development. However, in some tumor-rejection settings,
NK cell–mediated tumor rejection clearly does not require
NKT cell activity. Although NK cells were the primary ef-
fector cells in the intraperitoneal RM-1 tumor model, in
the intravenous RM-1 lung tumor model, NKT cells ap-
peared to also contribute to tumor protection. These data
support previous observations that NK cell–mediated clear-
ance of tumors from the peritoneum is quite a distinct pro-
cess, dependent strictly on perforin, and requiring TNF for
NK cell recruitment (36). In the lung, RM-1 rejection re-
quires NKT cells and IFN-g (data not shown), but not
TNF, and thus it is possible that the cytokine network ini-
tiating the NK cell response may be distinct at different tu-
mor sites. Importantly, a recent study by Carnaud et al. (46)
has suggested that with the appropriate activation, NKT
cells can rapidly produce IFN-g that activates NK cells. 
When comparing sarcoma induction by MCA in B6.P2/2
and B6.Ja2812/2 mice (Fig. 3 C), it is apparent that addi-
tional effector mechanisms may contribute to the protec-
tive response. In particular, the response of NKT cells to
cytokines (such as IL-12) or production of cytokines (such
as IFN-g) may also provide tumor protection by mecha-
nisms other than perforin-mediated cytotoxicity. Indeed,
ongoing experiments in IFN-g–deficient mice and mice
doubly deficient for IFN-g and perforin support an impor-
tant role for IFN-g in addition to perforin (Smyth, M.J.,
unpublished data). We have demonstrated here that after
activation with IL-12, NKT cells can directly lyse MCA-
induced tumors with negligible levels of MHC class I or
CD1d. This is not to say that NKT cells protect mice from
sarcoma development by direct lysis, as NK cells also lyse
MCA-1 tumor cells, but the data illustrate that direct tu-
mor cell lysis cannot be ruled out as a potential mechanism
of control. It remains to be determined whether TCR–
CD1d interactions are involved in direct lysis of MCA tumors
by activated NKT cells, and the role of CD1d in surveil-
lance against MCA-induced sarcoma needs to be examined
in CD1d-deficient mice. Several recent studies suggest that
DCs expressing CD1d may act as important APCs in innate
antitumor responses by NK and/or NKT cells (33, 41).
Further work will be required to dissect the dynamics be-
tween NK and NKT cells and APCs in vivo in this tumor
model.
Our work provides the first evidence that TCR Va14
Ja281 NKT cells may be critical in natural immune re-
sponses to spontaneous tumors. The demonstrated critical
role of Va14 NKT cells in controlling what are considered
weakly immunogenic sarcomas raises the question of
whether NKT cells may also play an important role in pro-
tection from more immunogenic tumors, such as those in-
duced by oncogenic viruses or UV light. Future work eval-
uating the role of NKT cells in other spontaneous tumor
models should provide greater insight into the immune
networks that constitute tumor surveillance.
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